Compare Stocks: CTNM, PBH, URGN, and RAPP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$15.14 -5.0%	$15.39	$8.60 ▼ $17.78	$599.68M	0.75	506,840 shs	388,829 shs
PBH Prestige Consumer Healthcare	$48.61 -2.4%	$50.90	$42.62 ▼ $71.07	$2.36B	0.33	429,118 shs	471,861 shs
RAPP Rapport Therapeutics	$43.88 -4.8%	$44.55	$22.06 ▼ $52.93	$2.21B	1.02	261,290 shs	437,737 shs
URGN Urogen Pharma	$45.00 +2.7%	$43.16	$15.86 ▼ $50.81	$2.14B	1.57	832,880 shs	1.02 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	-5.02%	-12.18%	+4.49%	+27.66%	+20.93%
PBH Prestige Consumer Healthcare	-2.39%	-8.13%	-7.93%	+2.00%	-26.33%
RAPP Rapport Therapeutics	-4.79%	-9.88%	-6.60%	+24.62%	+56.55%
URGN Urogen Pharma	+2.72%	+1.31%	-2.83%	+52.54%	+117.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$15.14 -5.0%	$15.39	$8.60 ▼ $17.78	$599.68M	0.75	506,840 shs	388,829 shs
PBH Prestige Consumer Healthcare	$48.61 -2.4%	$50.90	$42.62 ▼ $71.07	$2.36B	0.33	429,118 shs	471,861 shs
RAPP Rapport Therapeutics	$43.88 -4.8%	$44.55	$22.06 ▼ $52.93	$2.21B	1.02	261,290 shs	437,737 shs
URGN Urogen Pharma	$45.00 +2.7%	$43.16	$15.86 ▼ $50.81	$2.14B	1.57	832,880 shs	1.02 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	-5.02%	-12.18%	+4.49%	+27.66%	+20.93%
PBH Prestige Consumer Healthcare	-2.39%	-8.13%	-7.93%	+2.00%	-26.33%
RAPP Rapport Therapeutics	-4.79%	-9.88%	-6.60%	+24.62%	+56.55%
URGN Urogen Pharma	+2.72%	+1.31%	-2.83%	+52.54%	+117.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	2.40	Hold	$20.25	33.75% Upside
PBH Prestige Consumer Healthcare	2.17	Hold	$70.75	45.56% Upside
RAPP Rapport Therapeutics	3.00	Buy	$62.86	43.25% Upside
URGN Urogen Pharma	2.80	Moderate Buy	$50.38	11.94% Upside

Current Analyst Ratings Breakdown

Latest CTNM, PBH, URGN, and RAPP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/17/2026	RAPP Rapport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$75.00
8/17/2026	RAPP Rapport Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
8/12/2026	RAPP Rapport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $66.00
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/6/2026	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $58.00
8/6/2026	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $75.00
8/5/2026	URGN Urogen Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $60.00
8/5/2026	RAPP Rapport Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/28/2026	RAPP Rapport Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	11.39	N/A	N/A	$6.99 per share	2.17
PBH Prestige Consumer Healthcare	$1.10B	2.08	$5.08 per share	9.56	$39.89 per share	1.22
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$10.17 per share	N/A
URGN Urogen Pharma	$109.79M	20.03	N/A	N/A	($2.25) per share	-20.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.61	9.55	1.56	15.57%	11.39%	5.66%	11/5/2026 (Estimated)
RAPP Rapport Therapeutics	-$111.48M	-$3.04	N/A	N/A	N/A	N/A	-29.02%	-27.37%	11/5/2026 (Estimated)
URGN Urogen Pharma	-$153.49M	-$1.98	N/A	12.89	N/A	-51.73%	N/A	-43.79%	11/5/2026 (Estimated)

Latest CTNM, PBH, URGN, and RAPP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/5/2026	Q2 2026	RAPP Rapport Therapeutics	-$1.12	-$1.19	-$0.07	-$1.19	$2.22 million	N/A
8/5/2026	Q2 2026	URGN Urogen Pharma	-$0.2650	-$0.28	-$0.0150	-$0.28	$63.55 million	$72.46 million
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	3.91%	N/A	53.22%	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	37.17	37.17
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
RAPP Rapport Therapeutics	N/A	15.72	15.72
URGN Urogen Pharma	N/A	3.80	3.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
PBH Prestige Consumer Healthcare	99.95%
RAPP Rapport Therapeutics	N/A
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	7.90%
PBH Prestige Consumer Healthcare	1.50%
RAPP Rapport Therapeutics	12.48%
URGN Urogen Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
PBH Prestige Consumer Healthcare	540	47.38 million	46.66 million	Optionable
RAPP Rapport Therapeutics	N/A	47.98 million	41.99 million	N/A
URGN Urogen Pharma	200	48.88 million	46.54 million	Optionable

CTNM, PBH, URGN, and RAPP Headlines

Recent News About These Companies

Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock

September 9 at 3:07 PM | marketbeat.com

Jason Drew Smith Sells 1,519 Shares of Urogen Pharma (NASDAQ:URGN) Stock

September 9 at 3:07 PM | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Trading Up 5.9% - Here's What Happened

September 9 at 11:59 AM | marketbeat.com

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

September 8 at 9:35 AM | zacks.com

Legal & General Group Plc Invests $1.32 Million in Urogen Pharma $URGN

September 7 at 4:55 AM | marketbeat.com

Bank of New York Mellon Corp Buys New Position in Urogen Pharma $URGN

September 6, 2026 | marketbeat.com

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

UroGen Pharma to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN

August 30, 2026 | marketbeat.com

Deutsche Bank AG Takes $1.90 Million Position in Urogen Pharma $URGN

August 29, 2026 | marketbeat.com

Palo Alto Investors LP Purchases New Shares in Urogen Pharma $URGN

August 28, 2026 | marketbeat.com

Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN

August 28, 2026 | marketbeat.com

Coastal Bridge Advisors LLC Invests $1.36 Million in Urogen Pharma $URGN

August 28, 2026 | marketbeat.com

Elmind Capital LP Invests $4.42 Billion in Urogen Pharma $URGN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Position in Urogen Pharma $URGN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Acquires New Position in Urogen Pharma $URGN

August 25, 2026 | marketbeat.com

Mark Schoenberg Sells 60,677 Shares of Urogen Pharma (NASDAQ:URGN) Stock

August 25, 2026 | insidertrades.com

Urogen Pharma (NASDAQ:URGN) Insider Sells $2,854,852.85 in Stock

August 24, 2026 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages

August 23, 2026 | marketbeat.com

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

August 21, 2026 | zacks.com

UroGen Pharma Earnings Call Highlights ZUSDURI Surge

August 20, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, PBH, URGN, and RAPP Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$15.14 -0.80 (-5.02%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$15.14 +0.00 (+0.03%)

As of 09/9/2026 07:30 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Prestige Consumer Healthcare NYSE:PBH

$48.60 -1.19 (-2.38%)

Closing price 09/9/2026 03:59 PM Eastern

Extended Trading

$49.00 +0.40 (+0.81%)

As of 09/9/2026 07:36 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Rapport Therapeutics NASDAQ:RAPP

$43.88 -2.21 (-4.79%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$43.81 -0.07 (-0.16%)

As of 09/9/2026 07:48 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Urogen Pharma NASDAQ:URGN

$45.00 +1.19 (+2.72%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$44.84 -0.16 (-0.36%)

As of 09/9/2026 07:30 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, PBH, URGN, and RAPP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, PBH, URGN, and RAPP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, PBH, URGN, and RAPP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, PBH, URGN, and RAPP Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

Prestige Consumer Healthcare NYSE:PBH

Rapport Therapeutics NASDAQ:RAPP

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, PBH, URGN, and RAPP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, PBH, URGN, and RAPP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, PBH, URGN, and RAPP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, PBH, URGN, and RAPP Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

Prestige Consumer Healthcare NYSE:PBH

Rapport Therapeutics NASDAQ:RAPP

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools